Eliem Therapeutics agrees to acquire Tenet

2024-04-12
·
交易
Pharmaceutical Technology
临床1期并购
The combined company will advance the clinical development of TNT119 for autoimmune diseases. Credit: Dragana Gordic / Shutterstock.com.
US-based Eliem Therapeutics has announced a definitive agreemeTNT119 the autoimmune diseaseslopment-stage private biotechnology company Tenet Medicines.
The acquiEliem Therapeutics enhancing Eliem’s portfolio with a clinical-stage programme targeting unmet needs in autoimmune diseases.Tenet Medicines
The deal is supported by a securities Eliemase agreement in which Eliem will sell 31,238,282 shares at $3.84 eachautoimmune diseasese gross proceeds of $120m.
The private placement will see investments from investors includinEliemCapital Management, Boxer Capital, Deep Track Capital, Pontifax and Samsara Biocapital.
Following the acquisition and private placement, the cash reserves of the merged business wBoxer CapitalSamsara Biocapital
See Also:
Larimar Therapeutics gets grant for fusion protein for treating non-nuclear organelle associated disorders
Larimar Therapeutics gets grant for modified CAV-1 peptides for lung infection and injury treatment
This will support operations until 2027 and achieve significant milestones for TNT119, an anti-CD19 antibody.
Aileron Therapeuticsloped for autoimmune diseases including systlung infectionthematosus and immune thrombocytopenia.
The merged company plans to advance the development of this asset.
The boards of directors of Eliem and Tenet have given unanimous approval for thTNT119sactianti-CD19 antibody
Tenet CEO Stephen Thomas stated: “Our team brings deep experience in immune disorders and on the heels of positive preliminary Phase I data for TNT119 in membranous nephropathy, we are excited to begin Phase II clinical development in systemic lupus erythematosus and immune thrombocytopenia.
“We believe that TNT119 hasEliem-in-cTenetpotential and could be a transformative treatment option for many patients suffering from debilitating autoimmune disorders.
“This transaction and the support from leading life sciences investors will allow us to accelerate our development plans and continue advancing TNT119 for the potential benefit of patients.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
-
药物
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。